Renal Research Institute NY, USA; Institute of Biology and Molecular Genetics (BIOGEM), Ariano Irpino, Italy and Associazione Ipertensione Nefrologia e Trapianto Renale (IPNET), Reggio Calabria, Italy.
Clinical Epidemiology of Renal Diseases and Hypertension Unit, Consiglio Nazionale delle Ricerche (CNR) Institute of Clinical Physiology, Reggio Calabria, Italy.
Nephrol Dial Transplant. 2023 Jun 30;38(7):1700-1706. doi: 10.1093/ndt/gfad003.
Cold hemodialysis (HD) prevented intradialysis hypotension (IDH) in small, short-term, randomized trials in selected patients with IDH. Whether this treatments prevents IDH and mortality in the HD population at large is unknown.
We investigated the relationship between dialysate temperature and the risk of IDH, i.e. nadir blood pressure <90 mmHg (generalized estimating equation model) and all-cause mortality (Cox's regression) in an incident cohort of HD patients (n = 8071). To control for confounding by bias by indication and other factors we applied instrumental variables adjusting for case mix at facility level.
Twenty-seven percent of patients in the study cohort were systematically treated with a dialysate temperature ≤35.5°C. Over a median follow-up of 13.6 months (interquartile range 5.2-26.1 months), a 0.5°C reduction of the dialysate temperature was associated with a small (-2.4%) reduction of the risk of IDH [odds ratio (OR) 0.976, 95% confidence interval (CI) 0.957-0.995, P = .013]. In case-mix, facility-level adjusted analysis, the association became much stronger (OR 0.67, 95% CI 0.63-0.72, risk reduction = 33%, P < .001). In contrast, colder dialysate temperature had no effect on mortality both in the unadjusted [hazard ratio (HR) (0.5°C decrease) 1.074, 95% CI 0.972-1.187, P = .16] and case-mix-adjusted analysis at facility level (HR 1.01, 95% CI 0.88-1.16, P = .84). Similar results were registered in additional analyses by instrumental variables applying the median dialysate temperature or the facility percentage of patients prescribed a dialysate temperature <36°C. Further analyses restricted to patients with recurrent IDH fully confirmed these findings.
Cold HD was associated with IDH in the HD population but had no association with all-cause mortality.
在针对有 IDH 风险的小样本、短期随机试验中,低温血液透析(HD)预防了透析中低血压(IDH)。但这种治疗方法是否能预防一般 HD 患者的 IDH 和死亡率尚不清楚。
我们在一个 HD 患者的发病队列中(n=8071),用广义估计方程模型(GEE)分析透析液温度与 IDH 风险(即最低血压<90mmHg)的关系,并使用 Cox 回归分析全因死亡率。为了控制由指示性偏倚和其他因素引起的混杂,我们应用了仪器变量,根据设施水平调整病例组合。
研究队列中 27%的患者系统地接受了 ≤35.5°C 的透析液温度治疗。在中位数为 13.6 个月(四分位距为 5.2-26.1 个月)的随访中,透析液温度降低 0.5°C 与 IDH 风险降低 2.4%相关(比值比 0.976,95%置信区间 0.957-0.995,P=0.013)。在病例组合、设施水平调整分析中,这种关联变得更强(比值比 0.67,95%置信区间 0.63-0.72,风险降低 33%,P<0.001)。相反,在未调整分析(风险比(HR)(降低 0.5°C)1.074,95%置信区间 0.972-1.187,P=0.16)和设施水平的病例组合调整分析(HR 1.01,95%置信区间 0.88-1.16,P=0.84)中,低温透析液对死亡率均无影响。在应用透析液中位数或接受透析液温度<36°C 治疗的患者比例作为仪器变量的进一步分析中,也得到了类似的结果。进一步将分析仅限于有复发性 IDH 的患者,完全证实了这些发现。
在 HD 人群中,低温 HD 与 IDH 相关,但与全因死亡率无关。